TNK-tissue plasminogen activator in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 10a dose-ranging trial

Circulation

Volumn 95, Issue 2, 1997, Pages 351-356

  Cannon, Christopher P ^a   McCabe, Carolyn H ^a   Michael Gibson, C ^b   Ghali, Magdi ^c   Sequeira, Rafael F ^d   McKendall, George R ^e   Breed, Judy ^f   Modi, Nishit B ^f   Fox, Norma Lynn ^f   Tracy, Russell P ^g   Love, Ted W ^f   Braunwald, Eugene ^a,h  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c Iowa Heart Center (Des Moines)   (United States)

^d JACKSON MEMORIAL HOSPITAL   (United States)

^e RHODE ISLAND HOSPITAL   (United States)

^f GENENTECH INC   (United States)

^g UNIVERSITY OF VERMONT   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

myocardial infarction; plasminogen activators; reperfusion; thrombolysis

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; TNK TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 16944362757     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.2.351     Document Type: Article

References (12)

1. Braunwald E. The open-artery theory is alive and well: again. N Engl J Med. 1993:329:1650-1652.
2. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-401.
3. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial: phase I findings. N Engl J Med. 1985;312:932-936.
4. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD, Palmeri ST, Davis V, Gibson CM, Poole WK, Braunwald E, for the TIMI 4 Investigators. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol. 1994; 24:1602-1610.
5. Granger CE, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction. Drugs. 1992;44:293-325.
6. The GUSTO Angiographie Investigators. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
7. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
8. Cannon CP, Braunwald E. Time to reperfusion: the critical modulator in thrombolysis and primary angioplasty. J Thromb Thrombolysis. 1996:3:109-117.
9. Cannon CP, Antman EM, Walls R, Braunwald E. Time as an adjunctive agent to thrombolytic therapy. J Thromb Thrombolysis. 1994;l:27-34.
10. Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, Eisenberg M, for the Myocardial Infarction Triage and Intervention Project Group. Prehospital-initiated vs hospital-initiated thrombolytic therapy: Myocardial Infarction Triage and Intervention Trial. JAMA. 1993:270:1211-1216.
11. The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med. 1993:329:383-389.
12. Rawles J, on behalf of the GREAT Group. Halving of mortality at 1 year by domiciliary thrombolysis in the Gambian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol. 1994;23:l-5,